- AU$37.28m
- AU$23.71m
- AU$6.84m
Investor Presentation - September Quarterly Update
Quarterly Activities Report
PRE_NR Ends: 08:58:46
Appendix 4C Cash Flow Report
PRE_NR Ends: 08:56:25
Pharmaxis Quarterly Shareholder Update and Investor Briefing
PXS Doses First Patient in Phase 2 Bone Marrow Cancer Trial
PRE_NR Ends: 11:10:53
Brief: Pharmaxis Cleared To Progress To Phase 2 Bone Marrow Cancer Trial
PXS Cleared to Progress to Phase 2 Bone Marrow Cancer Trial
PRE_NR Ends: 08:44:59
Annual Report to shareholders
Notice of Annual General Meeting/Proxy Form
Appendix 4G
Corporate Governance Statement
Change in substantial holding
Change in substantial holding
Pharmaxis to Present at Biotech Webinar
Application for quotation of securities - PXS